vs
徕博科（LH）与Tractor Supply（TSCO）财务数据对比。点击上方公司名可切换其他公司
Tractor Supply的季度营收约是徕博科的1.0倍（$3.6B vs $3.5B），徕博科净利率更高（4.7% vs 4.6%，领先0.1%），Tractor Supply同比增速更快（100.0% vs 5.6%），过去两年徕博科的营收复合增速更高（5.2% vs -8.0%）
徕博科（Labcorp）是全球领先的生命科学与诊断检测企业，面向医疗机构、制药企业和个人患者提供全面的临床检验服务、药物研发支持及医疗检测解决方案，依托先进科研经验与创新技术输出准确可落地的健康洞察，助力临床决策、加快新药研发，提升全球患者健康水平。
Tractor Supply Company成立于1938年，是美国连锁零售企业，主营家居装修、农业、园艺养护、牲畜、马术及宠物护理相关设备与用品，客群覆盖农民、牧场主、宠物主及土地所有者。截至2024年共开设2250家门店，总部位于田纳西州布伦特伍德，为纳斯达克上市的财富500强企业。
LH vs TSCO — 直观对比
营收规模更大
TSCO
是对方的1.0倍
$3.5B
营收增速更快
TSCO
高出94.4%
5.6%
净利率更高
LH
高出0.1%
4.6%
两年增速更快
LH
近两年复合增速
-8.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.5B | $3.6B |
| 净利润 | $164.7M | $164.5M |
| 毛利率 | 28.2% | 36.2% |
| 营业利润率 | 7.6% | 6.5% |
| 净利率 | 4.7% | 4.6% |
| 营收同比 | 5.6% | 100.0% |
| 净利润同比 | 14.9% | 4.6% |
| 每股收益（稀释后） | $1.98 | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LHTSCO
| Q1 26 | — | $3.6B | ||
| Q4 25 | $3.5B | $3.9B | ||
| Q3 25 | $3.6B | $3.7B | ||
| Q2 25 | $3.5B | $4.4B | ||
| Q1 25 | $3.3B | $3.5B | ||
| Q4 24 | $3.3B | $3.8B | ||
| Q3 24 | $3.3B | $3.5B | ||
| Q2 24 | $3.2B | $4.2B |
净利润LHTSCO
| Q1 26 | — | $164.5M | ||
| Q4 25 | $164.7M | $227.4M | ||
| Q3 25 | $261.1M | $259.3M | ||
| Q2 25 | $237.9M | $430.0M | ||
| Q1 25 | $212.8M | $179.4M | ||
| Q4 24 | $143.4M | $236.4M | ||
| Q3 24 | $169.3M | $241.5M | ||
| Q2 24 | $205.3M | $425.2M |
毛利率LHTSCO
| Q1 26 | — | 36.2% | ||
| Q4 25 | 28.2% | 35.1% | ||
| Q3 25 | 28.8% | 37.4% | ||
| Q2 25 | 29.7% | 36.9% | ||
| Q1 25 | 28.3% | 36.2% | ||
| Q4 24 | 26.9% | 35.2% | ||
| Q3 24 | 27.6% | 37.2% | ||
| Q2 24 | 28.8% | 36.6% |
营业利润率LHTSCO
| Q1 26 | — | 6.5% | ||
| Q4 25 | 7.6% | 7.6% | ||
| Q3 25 | 11.1% | 9.2% | ||
| Q2 25 | 11.2% | 13.0% | ||
| Q1 25 | 9.7% | 7.2% | ||
| Q4 24 | 6.5% | 8.4% | ||
| Q3 24 | 7.7% | 9.4% | ||
| Q2 24 | 9.2% | 13.2% |
净利率LHTSCO
| Q1 26 | — | 4.6% | ||
| Q4 25 | 4.7% | 5.8% | ||
| Q3 25 | 7.3% | 7.0% | ||
| Q2 25 | 6.7% | 9.7% | ||
| Q1 25 | 6.4% | 5.2% | ||
| Q4 24 | 4.3% | 6.3% | ||
| Q3 24 | 5.2% | 7.0% | ||
| Q2 24 | 6.4% | 10.0% |
每股收益（稀释后）LHTSCO
| Q1 26 | — | $0.31 | ||
| Q4 25 | $1.98 | $0.42 | ||
| Q3 25 | $3.12 | $0.49 | ||
| Q2 25 | $2.84 | $0.81 | ||
| Q1 25 | $2.52 | $0.34 | ||
| Q4 24 | $1.72 | $-5.96 | ||
| Q3 24 | $2.00 | $2.24 | ||
| Q2 24 | $2.43 | $3.93 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $532.3M | $224.3M |
| 总债务越低越好 | — | $2.1B |
| 股东权益账面价值 | $8.6B | $2.5B |
| 总资产 | $18.4B | $11.7B |
| 负债/权益比越低杠杆越低 | — | 0.85× |
8季度趋势，按日历期对齐
现金及短期投资LHTSCO
| Q1 26 | — | $224.3M | ||
| Q4 25 | $532.3M | $194.1M | ||
| Q3 25 | $598.1M | $184.6M | ||
| Q2 25 | $647.3M | $225.8M | ||
| Q1 25 | $369.4M | $231.7M | ||
| Q4 24 | $1.5B | $251.5M | ||
| Q3 24 | $1.5B | $186.3M | ||
| Q2 24 | $265.1M | $394.7M |
总债务LHTSCO
| Q1 26 | — | $2.1B | ||
| Q4 25 | — | $150.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $150.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益LHTSCO
| Q1 26 | — | $2.5B | ||
| Q4 25 | $8.6B | $2.6B | ||
| Q3 25 | $8.7B | $2.6B | ||
| Q2 25 | $8.5B | $2.5B | ||
| Q1 25 | $8.3B | $2.2B | ||
| Q4 24 | $8.1B | $2.3B | ||
| Q3 24 | $8.2B | $2.3B | ||
| Q2 24 | $8.0B | $2.3B |
总资产LHTSCO
| Q1 26 | — | $11.7B | ||
| Q4 25 | $18.4B | $10.9B | ||
| Q3 25 | $18.3B | $10.9B | ||
| Q2 25 | $18.1B | $10.6B | ||
| Q1 25 | $17.6B | $10.4B | ||
| Q4 24 | $18.4B | $9.8B | ||
| Q3 24 | $18.6B | $9.8B | ||
| Q2 24 | $16.7B | $9.8B |
负债/权益比LHTSCO
| Q1 26 | — | 0.85× | ||
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $614.2M | $91.1M |
| 自由现金流经营现金流 - 资本支出 | $490.3M | — |
| 自由现金流率自由现金流/营收 | 13.9% | — |
| 资本支出强度资本支出/营收 | 3.5% | 5.6% |
| 现金转化率经营现金流/净利润 | 3.73× | 0.55× |
| 过去12个月自由现金流最近4个季度 | $1.2B | — |
8季度趋势，按日历期对齐
经营现金流LHTSCO
| Q1 26 | — | $91.1M | ||
| Q4 25 | $614.2M | $324.8M | ||
| Q3 25 | $387.2M | $307.9M | ||
| Q2 25 | $620.6M | $785.8M | ||
| Q1 25 | $18.5M | $216.8M | ||
| Q4 24 | $777.2M | $517.2M | ||
| Q3 24 | $277.3M | $86.3M | ||
| Q2 24 | $561.1M | $559.9M |
自由现金流LHTSCO
| Q1 26 | — | — | ||
| Q4 25 | $490.3M | $59.3M | ||
| Q3 25 | $280.5M | $30.3M | ||
| Q2 25 | $542.7M | $575.4M | ||
| Q1 25 | $-107.5M | $75.5M | ||
| Q4 24 | $665.1M | $271.2M | ||
| Q3 24 | $161.5M | $-101.9M | ||
| Q2 24 | $432.9M | $367.3M |
自由现金流率LHTSCO
| Q1 26 | — | — | ||
| Q4 25 | 13.9% | 1.5% | ||
| Q3 25 | 7.9% | 0.8% | ||
| Q2 25 | 15.4% | 13.0% | ||
| Q1 25 | -3.2% | 2.2% | ||
| Q4 24 | 20.0% | 7.2% | ||
| Q3 24 | 4.9% | -2.9% | ||
| Q2 24 | 13.4% | 8.6% |
资本支出强度LHTSCO
| Q1 26 | — | 5.6% | ||
| Q4 25 | 3.5% | 6.8% | ||
| Q3 25 | 3.0% | 7.5% | ||
| Q2 25 | 2.2% | 4.7% | ||
| Q1 25 | 3.8% | 4.1% | ||
| Q4 24 | 3.4% | 6.5% | ||
| Q3 24 | 3.5% | 5.4% | ||
| Q2 24 | 4.0% | 4.5% |
现金转化率LHTSCO
| Q1 26 | — | 0.55× | ||
| Q4 25 | 3.73× | 1.43× | ||
| Q3 25 | 1.48× | 1.19× | ||
| Q2 25 | 2.61× | 1.83× | ||
| Q1 25 | 0.09× | 1.21× | ||
| Q4 24 | 5.42× | 2.19× | ||
| Q3 24 | 1.64× | 0.36× | ||
| Q2 24 | 2.73× | 1.32× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
TSCO
暂无分部数据
